Mission: encourage and engage trainees for stem cell transplant/cellular therapy. Realize visions of young physicians/students in Europe, and wherever possible.
Registering as a stem cell donor can give someone a second chance at life. 💙
🌍 Today marks #WorldMarrowDonorDay. We recognise donors, registries, healthcare professionals and everyone involved in connecting patients with a suitable donor. Thank you for bringing hope to patients around the world, searching for a match. 🙏
Learn more: https://t.co/nULOrQXUG7
#ThankYouDonor #WMDD #WMDD26 #bonemarrowtransplant #HCT
📢 Today marks World Lymphoma Awareness Day. #WLAD2026
🗣️ Hear Kirsti's powerful story about navigating non-Hodgkin lymphoma and becoming the captain of her own survivorship.
ℹ️ This year’s campaign, Navigating Lymphoma and CLL Together, shines a light on patients' challenges, and recognises the important role of patient organisations.
No patient travels alone.
#lymphoma #nonhodgkinlymphoma #patientstory #survivorship #patientcare @knowyournodes
📢 Case submission and grant application deadline approaching for this first-of-its-kind EBMT meeting!
📋 Share your experience with the community and contribute to the scientific discussion: https://t.co/Zc1YUDRyxg
📍 Paris, France
📅 21-22 January 2027
#HCT#CellTherapy #MyeloidMalignancies #AcuteLeukemia #ChronicMalignancies
Do check out this 2-day hybrid course, bringing together 11 international speakers from the US and across Europe to share the latest advances in IEI: from novel gene discovery to advanced therapies.
https://t.co/UzNKZCxt93
That’s a wrap! What a special weekend we've had at #ITCTC26.
A huge thank you to all our chairs, speakers and attendees for making it such a great meeting, bringing together our community for three days of collaborative learning. 🙏
📅 Save the date for the 12th International Transplant and Cellular Therapy Course, returning to Barcelona in September 2027! We look forward to seeing you again. #ITCTC27
✈️ Wishing everyone safe travels home.
We are about to begin an exciting 3-day deep dive into cellular therapies and transplant science, as today marks the first day of the 11th International Transplant and Cellular Therapy Course. ✍️🎓
Get ready for inspiring scientific exchange, interactive learning and collaboration, and share your favourite moments on social media! 🤳 #ITCTC26
Who is joining us today? 👋⚕️
Are you looking to strengthen your statistical skills? 📊 Join EBMT statisticians and internationally recognised experts this October for four days of intensive training designed for clinicians and data managers. 🔬
➡️ Limited number of spots remain, save yours today: https://t.co/OEj8FRrkHt
#StatisticalCourse #DataAnalysis #DataManagement #ClinicalResearch #CellTherapy
📢 NEW: Submit your case and apply for a travel grant for the EBMT Transplantation and Cellular Therapy in Myeloid Malignancies meeting 📅 21-22 January 2027 in 📍 Paris.
📩 Learn more and share your work: https://t.co/DvC9lHfY4y
#HCT#CellTherapy#MyeloidMalignancies #Transplantation #MedicalEducation
🩸 September marks #BloodCancerAwarenssMonth — a time to raise awareness, and recognise people affected by blood cancers and the families, healthcare professionals, researchers and communities supporting them.
Together, we continue supporting the journey towards improved patient outcomes. 🏥🙏
#BloodCancer #PatientCare #Hematology
📢 Case submissions and travel grant applications are now open for the new joint meeting on Transplantation and Cellular Therapy in Myeloid Malignancies.
Share your work, contribute to the scientific programme and join colleagues in Paris in January 2027. 📩 Submit your case and apply for a travel grant: https://t.co/Zc1YUDRyxg
#HCT #CellTherapy #MyeloidMalignancies #Transplantation #MedicalEducation
Just two weeks to go until we meet for #ITCTC26 in 📍 Barcelona. ✍️ There is still time to register for three days of cutting-edge science, inspiring discussions and collaborative learning in transplantation and cellular therapy.
🔗 Sign up now and join us from 11–13 September: https://t.co/d8aPj1syr0
#HCT #CellTherapy #hematology #patientcare
It's the anniversary of the EBMT Registry. 🎉 Over the past year, the Registry has continued to grow, made possible by the commitment and reporting of our community, helping advance research and improve care for patients.🌍
Thank you to everyone contributing to this shared effort!
💡 Learn more and stay up-to-date with the latest Registry news: https://t.co/vcSIwxLqvA
#HCT #CellTherapy #EBMTRegistry #PatientCare
📣 Join the next Inborn Errors Working Party Live Forum Session on IEI 📣
🗓️ Tuesday 1 September
⏰ 16:00–17:00 CEST
This online meeting will feature challenging cases and expert-led discussion on HCT indication, timing, conditioning strategies, donor selection, and other procedural considerations.
➡️Register now: https://t.co/qXZAB5SjmX
#HCT #PatientCare #ClinicalCase #InbornErrors
📣 Master survival analysis and join a practical four-day course to build your statistical skills with expert guidance, specially designed for clinicians and data managers. 🐦 Early Bird rate available until 10 August.
🗓️ 19–22 October
📍 Leiden, Netherlands
Spots are limited, book yours today➡️ https://t.co/OEj8FRrkHt
#survivalanalysis #datacollection #statistics #educationalcourse
🗣️ Submit your case for the Educational Course on Infections and Complications After Stem Cell Transplantation and CAR T-cell Therapy.📍Madrid, Spain 📅 19-21 November
✈️ Travel Grants available!
Learn more ➡️ https://t.co/JquUCJQKT1
#HCT#celltherapy#casesubmission #educationalmeeting
🧬 Not all "Very Poor-Risk Cytogenetics’ MDS is the same with regard to allo-HCT outcome! A just published @TheEBMT study reveals a more "favorable" subgroup within a conventional ‘very poor risk’ cgn MDS allo-HCT cohort🧵👇
https://t.co/xaT8clo9w3
📊 The 5-Year Survival Split:
•Relative more Favorable Group (lacking abn5q, abn17p, or abn3q26): 46% OS
•Unfavorable Group (has 1+ of these mutations): 18% OS 📉
🔮 The Takeaway: A "very poor-risk" label needs evaluation . Patients lacking abn5q, abn17p, or abn3q26 or highly complex CGN see more durable survival, while those who have them have worse outcomes and require consideration to targeted peri-transplant strategies.
@TheEBMT_Trainee@CarmeloGurnari #MDSSm